Ph PharmaEssentia Corp. announced that it submitted the new drug registration of BESREMi 500mcg/ml solution for injection in prefilled syringe (Ropeginterferon alfa-2b) for PV to the Drug Office, Hong Kong Department of Health.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
353 TWD | +1.88% | +11.71% | +2.02% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.02% | 3.55B | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- 6446 Stock
- News PharmaEssentia Corporation
- PharmaEssentia Corp. Announces Submission of New Drug Registration of BESREMi (Ropeginterferon Alfa-2b) for PV in Hong Kong